Plasmapheresis with immunosuppressive therapy vs immunosuppressive therapy alone for rapidly progressive anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis [4]

Nephrology Dialysis Transplantation

Volumn 19, Issue 7, 2004, Pages 1935-1937

  Nakamura, Tsukasa ^c   Matsuda, Takaharu ^c   Kawagoe, Yosuhiro ^c   Ueda, Yoshihiko ^a   Ebihara, Isao ^b   Koide, Hikaru ^b  

^a DOKKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KOTO HOSPITAL   (Japan)

^c Kikkoman General Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOPHOSPHAMIDE; CYTOKINE; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PODOCALYXIN; PREDNISOLONE;

ADULT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIAGNOSTIC KIT; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; LETTER; MALE; MEDICAL DECISION MAKING; OUTCOMES RESEARCH; PLASMAPHERESIS; PODOCYTE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; SURVIVAL RATE;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; FEMALE; GLOMERULONEPHRITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PLASMAPHERESIS; PREDNISOLONE; TIME FACTORS;

EID: 3242687158     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh293     Document Type: Letter

References (10)

1. Furuta T, Hotta O, Horigome I et al. Decreased CD4 lymphocyte count as a marker predicting high mortality rate in managing ANCA related rapidly progressive glomerulonephritis. Nephron 2002; 91: 601-605
2. Hauer HA, Bajema IM, van Houwelingen HC et al. and the European Vasculitis Study Group (EUVAS). Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int 2002; 62: 1732-1742
3. Zauner I, Bach D, Braun N et al. Predictive value of initial histology and effect of plasmapheresis on long-term prognosis of rapidly progressive glomerulonephritis. Am J Kidney Dis 2002; 39: 28-35
4. Grcevska L, Polenakovic M, Stojkovski L, Polenakovic H. Plasmapheresis in treatment of acute oligoanuria in crescentic glomerulonephritis. Artif Organs 1998; 22: 827-830
5. Akimoto T, Ando Y, Ito C, Muto S, Kusano E, Asano Y. Effect of plasmapheresis as initial monotherapy in a case of anti-neutrophil cytoplasmic autoantibody positive crescentic glomerulonephritis. ASAIO J 1999; 45: 509-513
6. Tesar V, Jelinkova E, Masek Z et al. Influence of plasma exchange on serum levels of cytokines and adhesion molecules in ANCA-positive renal vasculitis. Blood Purif 1998; 16: 72-80
7. Nakamura T, Ushiyama C, Suzuki S et al. The urinary podocyte as a marker for the differential diagnosis of idiopathic focal glomerulosclerosis and minimal-change nephrotic syndrome. Am J Nephrol 2000; 20: 175-179
8. Nakamura T, Ushiyama C, Suzuki S et al. Urinary podocytes for the assessment of disease activity in lupus nephritis. Am J Med Sci 2000; 320: 112-116
9. Meyer TW, Bennett PH, Nelson RG. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with type II diabetes and micro albuminuria. Diabetologia 1999; 42: 1341-1344
10. Nakamura T, Ushiyama C, Hirokawa K et al. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant 2002; 17: 798-802